High expression level of T-box transcription factor 5 predicts unfavorable survival in stage I and II gastric adenocarcinoma

Abstract

The expression of T-box transcription factor 5 (TBX5) has previously been observed in human cancer. The aim of the present study was to investigate TBX5 expression and its potential clinical significance in gastric cancer (GC). Using reverse transcription-quantitative polymerase chain reaction, the TBX5 mRNA expression levels in 30 pairs of surgically resected healthy gastric tissues and early stage (stages I and II) GC tissues were evaluated. The TBX5 mRNA expression levels were increased in GC stage I and II tumor tissues (P=0.01, n=30) compared with the matched adjacent non-tumor tissue. However, no significant difference was observed in TBX5 mRNA expression levels in matched adjacent non-tumor tissue compared with the tumor tissue from stage III and IV GC samples (P=0.318, n=30). Immunohistochemical analysis for TBX5 expression was performed on 161 paraffin-embedded stage I and II GC tissue blocks. Statistical analysis was performed to evaluate the associations between TBX5 expression, clinicopathological factors and prognosis. Patients with stage I and II GC and tumors with high TBX5 expression levels presented poor overall survival (OS) rate (P=0.024). The Cox proportional hazards model analysis demonstrated that TBX5 expression was an independent risk factor (P=0.017). The present study indicates that high expression of TBX5 is associated with unfavorable OS rates in patients with stage I and II GC. In conclusion, the expression of TBX5 may be a valuable biomarker for the selection of cases of high-risk stage I and II GC.

TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma

“…Members of this family are involved in a variety of processes, including cell-cell signalling, proliferation, apoptosis, and migration [37]. Studies have shown that TBX5 dysregulation plays an important role in breast cancer [37], gastric cancer [38], oesophageal carcinoma [39,40], and colon cancer [41]. For example, the TBX5 mRNA expression level is significantly downregulated in colorectal cancer cells; its methylation rate is significantly higher in cancer tissues than in normal tissues; and overexpressing TBX5 can inhibit the growth of colorectal cancer cells, promote the apoptosis of cancer cells, and reduce the migration rate of cancer cells [41].…”

Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis

“…FLJ22536, recently identified as CASC15, is a putative mediator of neural growth and differentiation and a tumor suppressor in neuroblastoma (Russell et al, 2015), and in melanoma it is linked to disease progression and phenotype switching between proliferative and invasive states (Lessard et al, 2015). Other diagnostic genes lack well-defined roles in melanoma; however, in other cancer types, a number exhibit aberrant expression (Gao et al, 2015;Jiang et al, 2008;Makiyama et al, 2005) and/or methylation (Jones et al, 2013;Kikuchi et al, 2013;Lai et al, 2008;Li et al, 2015;Semaan et al, 2016;Song et al, 2015;Wimmer et al, 2002 GSE45266 validation set -27K methylation differentiation (Zha et al, 2012), or are diagnostic (Semaan et al, 2016;Song et al, 2015;Xing et al, 2015), prognostic (Dietrich et al, 2013;Galluzzi et al, 2013;Qiu et al, 2015;Zheng et al, 2015;Zhou et al, 2014), or predictive biomarkers (Tada et al, 2011). Our 40-CpG classifier for melanoma diagnosis may have advantages over other available approaches for melanoma diagnosis.…”

Overexpression of T-box Transcription Factor 5 (TBX5) Inhibits Proliferation and Invasion in Non-Small Cell Lung Carcinoma Cells

“…Recently, the novel tumor-regulating role of TBX5 has been discovered. High expression levels of TBX5 were found to be associated with an unfavorable survival rate in stages I and II of gastric adenocarcinoma 11 . Polymorphisms near the TBX5 gene were shown to be correlated with an increased risk for esophageal cancer.…”